The firm's lab services and product revenues fell year over year, but collaboration revenues increased during Q2.
The revenue growth was driven by an increase in collaboration revenues, which offset declines in product sales and lab services revenues.
The firm reported revenues of $990,912 compared to $1.0 million a year ago, as product sales dropped 23 percent and collaboration revenues rose 157 percent
The collaborative study includes testing urine samples from patients who have an increased risk for complicated urinary tract infections.
OpGen recently launched the first Acuitas test, which is designed to detect the most common bacterial causes of complicated urinary tract infections.
OpGen said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.
The Nasdaq has told the firm that it is in compliance with all applicable listing standards and that its meeting with a hearings panel has been cancelled.
The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.
In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."
Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.
Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.
In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.